 CUPERTINO, Calif., April 26, 2021 GLOBE NEWSWIRE -- Reviva Pharmaceuticals Holdings, Inc. NASDAQ: RVPH along with its subsidiaries, Reviva or the Company, a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system CNS, cardiovascular, metabolic, and inflammatory diseases, today announced the full details of its Phase 2 clinical trial for its lead drug candidate, RP5063 brilaroxazine for Acute Schizophrenia. 